Selective Cyclooxygenase-2 Inhibition: A Target in Cancer Prevention and Treatment

This publication has 100 references indexed in Scilit:

• NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions
  Published by Elsevier ,2002
• Role of p38 MAP kinases and ERK in mediating ultraviolet-B induced cyclooxygenase-2 gene expression in human keratinocytes
  Oncogene, 2001
• Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis
  JAMA, 2000
• The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
  New England Journal of Medicine, 2000
• Inhibition of lung tumourigenesis by sulindac: comparison of two experimental protocols
  Carcinogenesis: Integrative Cancer Research, 1997
• CYCLOOXYGENASE-2 INHIBITORS: A New Class of Anti-Inflammatory Agents That Spare the Gastrointestinal Tract
  Gastroenterology Clinics of North America, 1996
• The multistep nature of cancer
  Trends in Genetics, 1993
• Lipopolysaccharide induces prostaglandin H synthase-2 in alveolar macrophages
  Biochemical and Biophysical Research Communications, 1992
• Arachidonic acid metabolites in cutaneous carcinomas. Evidence suggesting that elevated levels of prostaglandins in basal cell carcinomas are associated with an aggressive growth pattern
  Archives of Dermatology, 1986
• PROSTAGLANDINS AND BREAST CANCER
  The Lancet, 1977